Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2013

01-10-2013 | Special Feature

The current status and future perspectives of clinical trial groups in Japan

Author: Hirofumi Mukai

Published in: Breast Cancer | Issue 4/2013

Login to get access

Excerpt

Our country’s environment surrounding clinical trials in the breast cancer field is characterized by the following; there are a lot of small clinical trial groups, most of which have no data center of their own; trial design and statistical analysis is shared by statisticians in a limited number of these groups, in the majority of which trial-participating physicians themselves are engaged in statistical analyses. …
Metadata
Title
The current status and future perspectives of clinical trial groups in Japan
Author
Hirofumi Mukai
Publication date
01-10-2013
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2013
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-013-0491-1

Other articles of this Issue 4/2013

Breast Cancer 4/2013 Go to the issue

Special Feature

An overview of the Japan Breast Cancer Research Group (JBCRG) activities

Acknowledgment

Acknowledgement to reviewers 2013

Special Feature

Current status and future perspectives of patient-reported outcome research in clinical trials for patients with breast cancer in Japan

Original Article

Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy

Original Article

A clinically relevant bi-cellular murine mammary tumor model as a useful tool for evaluating the effect of retinoic acid signaling on tumor progression

Special Feature

Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits